XenImmune Therapeutics
XenImmune Therapeutics is developing a novel antibody-enzyme fusion to target tumors and trigger the robust immune response known as hyper-acute rejection.
Location: Armonk, NY
Foundation Cornell Technology Licensed: 2022
The Center for Technology Licensing (CTL) is Cornell University's technology transfer office. We manage technology for Cornell's Ithaca campus, Weill Cornell Medicine, Cornell Tech, and Cornell AgriTech in Geneva.
XenImmune Therapeutics is developing a novel antibody-enzyme fusion to target tumors and trigger the robust immune response known as hyper-acute rejection.
Location: Armonk, NY
Foundation Cornell Technology Licensed: 2022